title: Heart Failure Progression in Hypertrophic Cardiomyopathy　- Possible Insights From Cardiopulmonary Exercise Testing.
abstract: BACKGROUND
  Heart failure (HF) progression and its complications represent major emergent concerns in hypertrophic cardiomyopathy (HCM). We investigated the possible adjunctive role of cardiopulmonary exercise testing (CPET) in predicting HF-related events. An exercise-derived risk model, theHYPertrophicExercise-derivedRiskHF(HYPERHF), has been developed.
  
  
  RESULTS
  A multicenter cohort of 620 consecutive HCM outpatients was recruited and followed (2007 to 2015). The endpoint was death from HF, cardiac transplantation, NYHA III-IV class progression, severe functional deterioration leading to hospitalization for septal reduction, and hospitalization for HF worsening. During a median follow-up of 3.8 years (25-75th centile: 2.3-5.3 years), 84 patients reached the endpoint. Peak circulatory power (peak oxygen consumption * peak systolic blood pressure), ventilatory efficiency and left atrial diameter were independently associated with the endpoint and, accordingly, integrated into the HYPERHFmodel (C index: 0.849; best cutoff value equal to 15%).
  
  
  CONCLUSIONS
  CPET is useful in the evaluation of HCM patients. In this context, the HYPERHFscore might allow early identification of those patients at high risk of HF progression and its complications. (Circ J 2016; 80: 2204-2211).
authors.affiliation: Department of Clinical and Molecular Medicine, University of Rome "La Sapienza"
authors.forename: Damiano
authors.initials: D
authors.lastname: Magrì
authors.forename: Federica
authors.initials: F
authors.lastname: Re
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Limongelli
authors.forename: Piergiuseppe
authors.initials: P
authors.lastname: Agostoni
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Zachara
authors.forename: Michele
authors.initials: M
authors.lastname: Correale
authors.forename: Vittoria
authors.initials: V
authors.lastname: Mastromarino
authors.forename: Caterina
authors.initials: C
authors.lastname: Santolamazza
authors.forename: Matteo
authors.initials: M
authors.lastname: Casenghi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Pacileo
authors.forename: Fabio
authors.initials: F
authors.lastname: Valente
authors.forename: Marco
authors.initials: M
authors.lastname: Morosin
authors.forename: Beatrice
authors.initials: B
authors.lastname: Musumeci
authors.forename: Erika
authors.initials: E
authors.lastname: Pagannone
authors.forename: Antonello
authors.initials: A
authors.lastname: Maruotti
authors.forename: Massimo
authors.initials: M
authors.lastname: Uguccioni
authors.forename: Massimo
authors.initials: M
authors.lastname: Volpe
authors.forename: Camillo
authors.initials: C
authors.lastname: Autore
mesh_terms: D000328:Adult; D000368:Aged; D002312:Cardiomyopathy, Hypertrophic / Q000150:complications / Q000503:physiopathology; D015331:Cohort Studies; D005080:Exercise Test; D005260:Female; D006333:Heart Failure / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors